U.S. markets closed
  • S&P Futures

    3,713.25
    +23.00 (+0.62%)
     
  • Dow Futures

    29,675.00
    +137.00 (+0.46%)
     
  • Nasdaq Futures

    11,385.00
    +99.25 (+0.88%)
     
  • Russell 2000 Futures

    1,727.00
    +12.10 (+0.71%)
     
  • Crude Oil

    83.81
    +0.18 (+0.22%)
     
  • Gold

    1,707.00
    +5.00 (+0.29%)
     
  • Silver

    20.77
    +0.18 (+0.88%)
     
  • EUR/USD

    0.9831
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    3.6510
    -0.1530 (-4.02%)
     
  • Vix

    30.10
    -1.52 (-4.81%)
     
  • GBP/USD

    1.1334
    +0.0014 (+0.13%)
     
  • USD/JPY

    144.6760
    +0.0560 (+0.04%)
     
  • BTC-USD

    19,567.96
    +472.34 (+2.47%)
     
  • CMC Crypto 200

    444.80
    +9.45 (+2.17%)
     
  • FTSE 100

    6,908.76
    +14.95 (+0.22%)
     
  • Nikkei 225

    26,781.98
    +566.19 (+2.16%)
     

Spero Therapeutics Shares Jump After Upbeat FDA Feedback For Tebipenem HBr Program

·1 min read
  • Spero Therapeutics Inc (NASDAQ: SPROreceived minutes from a recent Type A meeting with the FDA, discussing steps required to resubmit the marketing application for tebipenem HBr for complicated urinary tract infection (cUTI).

  • During the Type A meeting, the FDA indicated that positive results from an additional Phase 3 trial supported by confirmatory nonclinical efficacy evidence could be sufficient to support the approval of tebipenem HBr for cUTI, including pyelonephritis for a limited use indication.

  • Spero and the FDA also aligned the key components of the proposed pivotal Phase 3 trial design, which may be the subject of a Special Protocol Assessment request, to be confirmed once the clinical protocol is finalized.

  • Spero received a Complete Response Letter from the FDA in June 2022, citing data from Spero's initial Phase 3 cUTI clinical trial, ADAPT-PO, that were insufficient to support approval.

  • Also read: FDA Identifies Review Issues For Spero's Tebipenem Application, Shares Plunge.

  • Spero plans to advance tebipenem HBr's clinical development and potential commercialization through external partnership.

  • If approved, tebipenem HBr would be the first oral carbapenem antibiotic to receive FDA approval.

  • Price Action: SPRO shares are up 10.50% at $0.80 on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.